Rapport Therapeutics Inc
RAPP26.058USD
-0.882-3.27%
交易中 （美東）報價延遲15分鐘
951.07M總市值
虧損本益比TTM
關於 Rapport Therapeutics Inc 公司
Rapport Therapeutics, Inc. 是一家臨牀階段的生物製藥公司，專注於發現和開發一系列精準小分子候選產品。該公司專注於開發一類新型精準神經藥物，旨在爲患者提供現有中樞神經系統疾病治療方法的替代方案。該公司爲患有中樞神經系統 (CNS) 疾病的患者推進了一系列治療方案，包括局竈性癲癇、疼痛、躁鬱症和聽力障礙。該公司的離子型穀氨酸受體 (iGluR) 是由神經遞質穀氨酸激活的配體門控離子通道。該公司的 RAP-219 是一種臨牀階段的小分子，旨在通過選擇性靶向一種稱爲 TARPy8 的 RAP 來實現神經解剖學特異性，TARPy8 與神經元 AMPAR 相關，後者是臨牀驗證的癲癇靶點。
Rapport Therapeutics Inc簡介
公司代碼RAPP
公司名稱Rapport Therapeutics Inc
上市日期Jun 07, 2024
CEOMr. Abraham N. (Abe) Ceesay
員工數量69
證券類型Ordinary Share
年結日Jun 07
公司地址99 High Street
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02110
電話18573218020
網址https://www.rapportrx.com/
公司代碼RAPP
上市日期Jun 07, 2024
CEOMr. Abraham N. (Abe) Ceesay
Rapport Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
743.04K
-0.78%
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
477.64K
--
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
409.64K
-2.03%
Ms. Cheryl Gault
Ms. Cheryl Gault
Chief Operating Officer
Chief Operating Officer
171.93K
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Chief Financial Officer
Chief Financial Officer
10.00K
--
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. James I. Healey, M.D., Ph.D.
Dr. James I. Healey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert J. (Rob) Perez
Mr. Robert J. (Rob) Perez
Independent Director
Independent Director
--
--
Ms. Wendy B. Young, Ph.D.
Ms. Wendy B. Young, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reid Huber, Ph.D.
Mr. Reid Huber, Ph.D.
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
743.04K
-0.78%
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
477.64K
--
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
409.64K
-2.03%
Ms. Cheryl Gault
Ms. Cheryl Gault
Chief Operating Officer
Chief Operating Officer
171.93K
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Chief Financial Officer
Chief Financial Officer
10.00K
--
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 9月29日 週一
更新時間: 9月29日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Third Rock Ventures, LLC
17.58%
Fidelity Management & Research Company LLC
11.87%
ARCH Venture Partners
8.09%
Capital World Investors
7.38%
Cormorant Asset Management, LP
6.38%
其他
48.71%
持股股東
持股股東
佔比
Third Rock Ventures, LLC
17.58%
Fidelity Management & Research Company LLC
11.87%
ARCH Venture Partners
8.09%
Capital World Investors
7.38%
Cormorant Asset Management, LP
6.38%
其他
48.71%
股東類型
持股股東
佔比
Investment Advisor
38.07%
Venture Capital
34.21%
Hedge Fund
8.83%
Investment Advisor/Hedge Fund
5.39%
Individual Investor
4.87%
Research Firm
2.81%
Bank and Trust
0.56%
Pension Fund
0.01%
Insurance Company
0.01%
其他
5.23%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
164
41.45M
89.90%
-333.41K
2025Q2
154
43.38M
118.86%
+3.70M
2025Q1
149
47.96M
131.36%
+9.87M
2024Q4
117
46.27M
126.51%
+9.23M
2024Q3
91
39.09M
106.87%
+12.18M
2024Q2
48
37.49M
102.49%
+37.49M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Third Rock Ventures, LLC
8.10M
17.58%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.47M
11.87%
-11.84K
-0.22%
Jun 30, 2025
ARCH Venture Partners
3.73M
8.09%
--
--
Jun 30, 2025
Capital World Investors
2.60M
5.64%
--
--
Jun 30, 2025
Cormorant Asset Management, LP
2.94M
6.38%
--
--
Jun 30, 2025
Capital International Investors
2.60M
5.64%
--
--
Jun 30, 2025
Sofinnova Investments, Inc
1.95M
4.22%
-48.02K
-2.41%
Sep 12, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.50M
5.42%
--
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.50M
3.25%
+451.25K
+43.03%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.24M
2.68%
-9.28K
-0.75%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
1.92%
iShares Neuroscience and Healthcare ETF
0.92%
ALPS Medical Breakthroughs ETF
0.63%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.92%
iShares Neuroscience and Healthcare ETF
佔比0.92%
ALPS Medical Breakthroughs ETF
佔比0.63%
Invesco Nasdaq Biotechnology ETF
佔比0.11%
iShares Micro-Cap ETF
佔比0.11%
ProShares Ultra Nasdaq Biotechnology
佔比0.11%
iShares Biotechnology ETF
佔比0.05%
iShares Russell 2000 Value ETF
佔比0.04%
Avantis US Small Cap Equity ETF
佔比0.03%
ProShares Hedge Replication ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
